—A Decision Resources’ Biosimilars Advisory Service Webinar
As part of our Biosimilars Advisory Service, Decision Resources is offering an exclusive webinar entitled Clinical Strategies to Maximize the Commercial Significance of Your Biosimilar for Oncology Indications. This webinar is open ONLY to subscribers of Decision Resources’ Biosimilars Advisory Service.
Please contact us to learn how you can purchase this service and attend the webinar.
Among the top five most commercially successful agents in oncology, four are biologic agents. Biosimilar versions of these drugs in oncology are poised to capture significant commercial success through 2020. However, major barriers present considerable obstacles in delivering this potential and some biosimilar developers may struggle to capture a slice of this highly attractive market segment. Despite the mixed speed and depth of uptake of biosimilar versions of Amgen’s Neupogen (filgrastim) in Europe to date, Decision Resources forecasts that biosimilars in oncology across the seven major pharmaceutical markets will reach sales in excess of $6.5 billion in 2020. Navigating the optimal route to bringing biosimilars to market is particularly uncertain in oncology as it is a therapeutic area with enormous commercial potential, high unmet medical need and diverse patient populations.
Presented by Biosimilars Advisory Service Director Andrew Merron, Ph.D., and based on findings from Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, this webinar will discuss identified strategies that can help biosimilar manufacturers find their way through the maze of possibilities in biosimilar development to achieve the greatest acceptance and uptake of their agent.
This presentation will answer the following questions:
- Which targets are the most commercially attractive for biosimilar developers looking for success within oncology indications? Why are these targets compelling?
- What is the optimal clinical trial design for biosimilars manufacturers in order to maximize uptake immediately following launch?
- What are the main barriers facing biosimilar manufacturers? How can these hurdles be most effectively cleared?
- How can biosimilar manufacturers position their agents in development to garner greatest commercial reward?
- What level of sales can manufacturers expect to achieve for biosimilar monoclonal antibodies and granulocyte-colony stimulating factors (G-CSFs)? Which companies stand to gain and lose the most?
Dr. Merron will conduct a live Q&A following the presentation.
Clinical Strategies to Maximize the Commercial Significance of Your Biosimilar for Oncology Indications
November 28, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Andrew Merron Ph.D., is the Biosimilars Advisory Service Product Director at Decision Resources. Prior to managing the Biosimilars Advisory Service, Dr. Merron was a senior analyst in the oncology department at Decision Resources. Dr. Merron has extensive experience in forecasting oncology and hematology-oncology drug markets. Dr. Merron also has considerable experience in conducting primary research with physicians and payers across the major pharmaceutical markets. Through his analyses, Dr. Merron identifies key market findings and highlights their strategic importance. Prior to joining Decision Resources, Dr. Merron received his B.Sc. in biochemistry from the University of Bath and his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses.To learn how you can purchase the Biosimilars Advisory Service and attend the webinar, please contact us using the information below.
In North America: Keith Rourke | 781-993-2656
In Europe: Kaj van Langendonck | +32-2-357-06-14
In Japan: Makiko Yoshimoto | +81-3-5401-2615
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
